[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Minneapolis Heart Institute Foundation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":194},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,68,100,124,151,175],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100642512","opn-balloon-for-safe-recanalization-of-calcified-coronary-lesions-100642512",false,"NCT07646444","OPN Balloon for SAFE Recanalization of Calcified Coronary Lesions","OPN Balloon for SAFE Recanalization of Calcified Coronary Lesions (OPEN-SAFE Registry)","OPEN-SAFE","Inclusion Criteria:\n\n* Age 18 years or older\n* Subjects who underwent a clinically indicated PCI procedure that involved at least one OPN balloon\n* Date range for data collection will be from February 1, 2023 to December 31, 2028\n\nExclusion Criteria:\n\n* Subjects who have opted out of being included in research related data collection","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","1 Week","OBSERVATIONAL","The goal of the OPEN-SAFE registry is to describe the contemporary use and outcomes of SIS-OPN in North America.",[26,27,28],"Coronary Arterial Disease (CAD)","In Stent Restenosis","Calcified Coronary Lesions","NOT_YET_RECRUITING","2026-06-10",{"date":32,"type":33},"2026-06-12","ACTUAL",{"date":35,"type":21},"2026-06",{"date":37,"type":21},"2027-06",{"name":39,"class":40},"Minneapolis Heart Institute Foundation","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100603062","secondary-mitral-regurgitation-treatment-with-mitraclip-and-assessment-by-cardiac-magnetic-resonance-100603062","NCT07131631","Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance","SMARTER-CMR","Inclusion Criteria:\n\n1\\. Adult patients (≥ 18 years old) with heart failure and reduced ejection fraction (LVEF \\\u003C 50% defined by echocardiography), medically and device-optimized according to guidelines, with significant FMR undergoing TEER with FDA-approved MitraClip device (Abbott Structural, USA)\n\nExclusion Criteria:\n\n1. Concomitant PCI and TEER\n2. Congenital heart disease\n3. Stage D heart failure\n4. Uncontrolled atrial fibrillation\n5. Pregnancy\n6. \\> moderate tricuspid regurgitation\n7. \\>moderate aortic regurgitation or stenosis\n8. Contraindications or unable to undergo CMR\n9. Prior mitral valve repair or replacement",{"count":49,"type":21},125,"This is a multi-center, prospective, observational study designed to evaluate the impact of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical outcomes post TEER. The target sample will be up to 125 patients enrolled to achieve 100 evaluable at 6 months of follow-up. Enrollment will occur at up to eight centers.",[52,53],"Heart Failure and Reduced Ejection Fraction","Functional Mitral Regurgitation",[55,56,57],"heart failure","reduced ejection fraction","functional mitral regurgitation","RECRUITING","2025-12-16",{"date":61,"type":33},"2025-12-23",{"date":63,"type":33},"2022-03-03",{"date":65,"type":21},"2027-07",{"name":39,"class":40},6,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100577952","phase-4-desifor-expand-mhif-100577952","NCT06804980","DESIFOR-EXPAND (MHIF)","The DEterminig Statin Intolerance for Rosuvastatin Trial","Inclusion Criteria:\n\n* Adult patients (≥ 21 years old) with a prior history of statin intolerance. Statin intolerance is defined by discontinuation of at least 2 different statin medications due to possible side effects. Patients can participate in the trial while on other lipid-lowering agents, such as ezetimibe and PSCK9 inhibitors, as long as the patient has been on the other lipid lowering therapy and tolerating it well for at least 1 month. For individuals with established ASCVD or multiple ASCVD risk factors, initiation of other lipid lowering therapy prior to participation in DESIFOR is encouraged.\n* 2\\. At least 30 days since discontinued use of a statin\n\nExclusion Criteria:\n\n* Women who are pregnant, nursing or attempting to become pregnant\n* Individuals who experienced severe reactions in the past, including rhabdomyolysis, severe myositis, anaphylaxis\n* Individuals who are not otherwise clinically indicated to take rosuvastatin 20 mg","21 Years",{"count":77,"type":21},100,"INTERVENTIONAL",[80],"PHASE4","The DESIFOR pilot study was conducted to determine the feasibility of utilizing an n-of-1 trial to facilitate tolerance of unblinded rosuvastatin in patients with prior statin intolerance",[83,84,85],"Statin Therapy","Statin Adverse Reaction","Statin",[87,88,89,90],"Statin Intolerance","lipid-lowering medication","LDL","LDL Cholesterol","2025-01-28",{"date":93,"type":33},"2025-02-03",{"date":95,"type":21},"2025-02-01",{"date":97,"type":21},"2026-12-31",{"name":39,"class":40},1,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":78,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":67},"100368472","radial-vs-state-of-the-art-femoral-access-for-bleeding-and-access-site-complication-reduction-in-cardiac-catheterization-rebirth-100368472","NCT04077762","Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)","Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access SIte Complication Reduction in Cardiac Catheterization (REBIRTH)","REBIRTH","Inclusion Criteria:\n\n* Age 18 years and older\n* Undergoing diagnostic angiography for ischemic symptoms with possible PCI, or undergoing planned urgent or elective PCI\n* Has provided informed consent and agrees to participate\n* Patients must be equally eligible to undergo cardiac catheterization via radial or femoral access\n\nExclusion Criteria:\n\n* Primary PCI for STEMI\n* Planned right heart catheterization\n* Valvular heart disease requiring valve surgery within 30 days after the index procedure\n* Hemodialysis access (arteriovenous fistula or graft) in the arm to be used for PCI in case of assignment to radial approach (the opposite arm may be used for radial access if a dialysis graft is present in one)\n* Peripheral arterial disease prohibiting vascular access\n* Presence of bilateral internal mammary artery coronary bypass grafts\n* International normalized ratio ≥1.5 while treated with oral vitamin K antagonists (i.e. warfarin) Receipt of oral factor Xa or IIa inhibitors ≤24 h before procedure\n* Planned staged PCI within 30 days after index procedure.\n* Any planned surgeries within 30 days after index procedure\n* Planned dual arterial access (for example for chronic total occlusion PCI)\n* Coexisting conditions that limit life expectancy to less than 30 days\n* Positive pregnancy test",{"count":109,"type":21},3266,[111],"NA","This is a phase IV, prospective, open label, randomized-controlled study that will compare radial access with state-of-the-art femoral access in patients without ST-segment elevation acute myocardial infarction undergoing cardiac catheterization. Subjects will be randomized 1:1 into 2 treatment groups: radial access and state-of-the-art femoral access. Randomization will be performed in blocks of 50 per site. Similarly, a second sub-randomization will be performed in the femoral access group into use of 18 vs 21 gauge needles, also in a 1:1 fashion.",[114,115],"Patient Satisfaction","Vascular Access Complication","2025-01-22",{"date":118,"type":33},"2025-01-24",{"date":120,"type":33},"2019-11-15",{"date":122,"type":21},"2028-08-19",{"name":39,"class":40},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":78,"phases":134,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":99},"100462763","phase-2-sodium-glucose-co-transporter-2-sglt2-and-stemi-100462763","NCT05305911","Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI","Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition Improves Left Ventricular Function and Reduces Adverse Left-Ventricular Remodeling in High-Risk Patients with Microvascular Obstruction (MVO) Following ST-elevation Myocardial Infarction (STEMI).","Inclusion Criteria:\n\n* Patients with their first STEMI (\\>18 years) who underwent successful primary PCI and able to give informed consent\n* At least mild LV dysfunction (LVEF \\\u003C 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI\n* Infarct size that is \\> 10% of LV mass\n* The presence of MVO that is \\> 10% of infarct size\n\nExclusion Criteria:\n\n* Contraindication to cardiac MRI\n* Life expectancy \\\u003C 1 year\n* Previous CABG or Valve Surgery\n* Previous STEMI\n* Pregnant or planning to become pregnant or lactating women\n* Cardiogenic shock (not resolved)\n* Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs)\n* GFR\\\u003C30 ml\u002Fmin\u002F1.73m2 or end-stage renal disease on dialysis\n* Type 1 diabetes mellitus or history of diabetic ketoacidosis\n* Type I or II diabetes with insulin use\n* Prior intolerance of SGLT2 inhibitors\n* Current use of SGLT2 inhibitors (randomized patients only)\n* Contraindications to gadolinium","75 Years",{"count":133,"type":21},81,[135],"PHASE2","The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.",[138,139],"Heart Attack","Enlarged Heart",[141,142],"Dapagliflozin","Sodium Glucose Co-Transporter 2","2024-10-03",{"date":145,"type":33},"2024-10-08",{"date":147,"type":33},"2022-08-03",{"date":149,"type":21},"2028-12",{"name":39,"class":40},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":160,"conditions":161,"keywords":164,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":99},"100447019","progress-bifurcation-global-registry-100447019","NCT05100992","Progress Bifurcation Global Registry","Prospective Global Registry of Percutaneous Coronary Intervention in Bifurcation Lesions (PROGRESS-BIFURCATION)","Inclusion Criteria:\n\n* Over 18 years of age\n* undergoing bifurcation percutaneous coronary intervention",{"count":159,"type":21},4000,"Coronary bifurcation lesions are lesions (or blockages) that occur at or near the intersection of a major coronary artery and one of the arteries' side branches.\n\nNumerous techniques and devices have been developed to treat coronary bifurcations; however, these types of lesions remain some of the most challenging, both in terms of procedural success and outcome. This study is designed as an observational, multi-center registry that will collect information on treatment strategies and outcomes of consecutive patients undergoing percutaneous coronary interventions (PCI) in coronary bifurcations among various participating centers, in order to determine the frequency of bifurcation PCI, the procedural strategies utilized, and the procedural outcomes.",[162,163],"Coronary Artery Disease","Coronary Bifurcation Lesions",[165,166],"bifurcation lesions","percutaneous coronary intervention","2021-10-20",{"date":169,"type":33},"2021-10-29",{"date":171,"type":33},"2020-04-23",{"date":173,"type":21},"2030-01",{"name":39,"class":40},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":99},"100447015","progress-complication-100447015","NCT05100940","Progress Complication","Prospective Global Registry of Complications of Percutaneous Coronary Interventions","* Over 18 years of age\n* undergoing coronary angiography or PCI\n* A complication occurred during or after the procedure",{"count":159,"type":21},"Coronary angiography and percutaneous coronary intervention (PCI) is often performed in patients with ischemic heart disease. The safety of PCI has improved with new devices and strategies, but complications still occur, especially during complex procedures. The objectives of this multi-center observational registry are to examine frequency of complications occuring during cardiac catheterization and PCI, examine procedural strategies utilized for complication management, and evaluate the clinical outcomes (both immediate and during follow-up.)",[162],[186,187],"complications","Percutaneous Coronary intervention",{"date":169,"type":33},{"date":190,"type":33},"2020-11-24",{"date":192,"type":21},"2030-12-31",{"name":39,"class":40},""]